GSK256073 acutely regulates NEFA levels via HCA2 agonism but does not achieve durable glycaemic control in type 2 diabetes. A randomised trial
This study investigated safety and efficacy of GSK256073, an in vitro potent, selective GPR109A agonist, for treatment of subjects with type 2 diabetes mellitus (Type 2 DM) poorly controlled with metformin alone. Patients with Type 2 DM (n=94) were enroled into this randomised, double-blind (sponsor...
Saved in:
Published in | European journal of pharmacology Vol. 755; pp. 95 - 101 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier B.V
15.05.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | This study investigated safety and efficacy of GSK256073, an in vitro potent, selective GPR109A agonist, for treatment of subjects with type 2 diabetes mellitus (Type 2 DM) poorly controlled with metformin alone.
Patients with Type 2 DM (n=94) were enroled into this randomised, double-blind (sponsor unblinded), placebo-controlled, parallel group trial. Participants received placebo for two weeks before being randomised (2:2:2:2:1:1) to receive doses of GSK256073 5mg twice-daily (BID), 10mg once-daily (QD), 25mg BID, 50mg QD or placebo BID or QD in addition to their current metformin treatment. The primary efficacy endpoint was change from baseline in glycosylated haemoglobin (HbA1c) at week 12. The safety profile of GSK256073 did not significantly differ from that of placebo. Decreases from baseline in HbA1c were observed in all treatment groups but were not statistically significant compared to placebo; at week 12 a maximum decrease of 0.30% from placebo was reached in the GSK256073 50mg QD group. On day 2, GSK256073 significantly decreased non-esterified fatty acid (NEFA) (0–12h) concentrations but pharmacological activity was lost (5mg BID, 10mg QD, 25mg BID) or reduced (50mg QD) at week 6. Drug exposure demonstrated 2-fold accumulation over 6 weeks.
The primary efficacy objective of the study was not met. GSK256073 did not improve HbA1c concentrations at week 12. Despite sustained drug exposure, the ability of the HCA2 agonist to suppress plasma NEFA concentrations waned over time and targeted effects on glucose oxidation and insulin sensitivity subsided. |
---|---|
AbstractList | This study investigated safety and efficacy of GSK256073, an in vitro potent, selective GPR109A agonist, for treatment of subjects with type 2 diabetes mellitus (Type 2 DM) poorly controlled with metformin alone.
Patients with Type 2 DM (n=94) were enroled into this randomised, double-blind (sponsor unblinded), placebo-controlled, parallel group trial. Participants received placebo for two weeks before being randomised (2:2:2:2:1:1) to receive doses of GSK256073 5mg twice-daily (BID), 10mg once-daily (QD), 25mg BID, 50mg QD or placebo BID or QD in addition to their current metformin treatment. The primary efficacy endpoint was change from baseline in glycosylated haemoglobin (HbA1c) at week 12. The safety profile of GSK256073 did not significantly differ from that of placebo. Decreases from baseline in HbA1c were observed in all treatment groups but were not statistically significant compared to placebo; at week 12 a maximum decrease of 0.30% from placebo was reached in the GSK256073 50mg QD group. On day 2, GSK256073 significantly decreased non-esterified fatty acid (NEFA) (0–12h) concentrations but pharmacological activity was lost (5mg BID, 10mg QD, 25mg BID) or reduced (50mg QD) at week 6. Drug exposure demonstrated 2-fold accumulation over 6 weeks.
The primary efficacy objective of the study was not met. GSK256073 did not improve HbA1c concentrations at week 12. Despite sustained drug exposure, the ability of the HCA2 agonist to suppress plasma NEFA concentrations waned over time and targeted effects on glucose oxidation and insulin sensitivity subsided. This study investigated safety and efficacy of GSK256073, an in vitro potent, selective GPR109A agonist, for treatment of subjects with type 2 diabetes mellitus (Type 2 DM) poorly controlled with metformin alone. Patients with Type 2 DM (n=94) were enroled into this randomised, double-blind (sponsor unblinded), placebo-controlled, parallel group trial. Participants received placebo for two weeks before being randomised (2:2:2:2:1:1) to receive doses of GSK256073 5mg twice-daily (BID), 10mg once-daily (QD), 25mg BID, 50mg QD or placebo BID or QD in addition to their current metformin treatment. The primary efficacy endpoint was change from baseline in glycosylated haemoglobin (HbA1c) at week 12. The safety profile of GSK256073 did not significantly differ from that of placebo. Decreases from baseline in HbA1c were observed in all treatment groups but were not statistically significant compared to placebo; at week 12 a maximum decrease of 0.30% from placebo was reached in the GSK256073 50mg QD group. On day 2, GSK256073 significantly decreased non-esterified fatty acid (NEFA) (0-12h) concentrations but pharmacological activity was lost (5mg BID, 10mg QD, 25mg BID) or reduced (50mg QD) at week 6. Drug exposure demonstrated 2-fold accumulation over 6 weeks. The primary efficacy objective of the study was not met. GSK256073 did not improve HbA1c concentrations at week 12. Despite sustained drug exposure, the ability of the HCA2 agonist to suppress plasma NEFA concentrations waned over time and targeted effects on glucose oxidation and insulin sensitivity subsided. |
Author | Dobbins, Robert Ambery, Philip Byerly, Robert Le Monnier de Gouville, Anne-Charlotte Mahar, Kelly Napolitano, Antonella Gao, Feng Gaddy, Riley |
Author_xml | – sequence: 1 givenname: Robert surname: Dobbins fullname: Dobbins, Robert organization: GlaxoSmithKline, Drug Discovery, Research Triangle Park, NC, USA – sequence: 2 givenname: Robert surname: Byerly fullname: Byerly, Robert organization: GlaxoSmithKline, Drug Discovery, Research Triangle Park, NC, USA – sequence: 3 givenname: Riley surname: Gaddy fullname: Gaddy, Riley organization: GlaxoSmithKline, Drug Discovery, Research Triangle Park, NC, USA – sequence: 4 givenname: Feng surname: Gao fullname: Gao, Feng organization: GlaxoSmithKline, Quantitative Sciences, Upper Merion, PA, USA – sequence: 5 givenname: Kelly surname: Mahar fullname: Mahar, Kelly organization: GlaxoSmithKline, Quantitative Sciences, Upper Merion, PA, USA – sequence: 6 givenname: Antonella surname: Napolitano fullname: Napolitano, Antonella organization: GlaxoSmithKline, Immuno-Inflammation Therapeutic Area, Stevenage, UK – sequence: 7 givenname: Philip surname: Ambery fullname: Ambery, Philip organization: Department of Endocrinology and Diabetes, Addenbrooke’s Hospital, Cambridge, UK – sequence: 8 givenname: Anne-Charlotte surname: Le Monnier de Gouville fullname: Le Monnier de Gouville, Anne-Charlotte email: anne-charlotte.m.degouville@gsk.com organization: GlaxoSmithKline, Drug Discovery, Laboratoire GSK, 27av du Quebec, 91951 les Ulis Cedex, France |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25773496$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc1uEzEUhS1URNPCGyDkJZsZbI_HHm-Qoqg_iAoWwNry2DepI8842J5IeYk-M65SWLK6m--cc3XOFbqY4wwIvaekpYSKT_sW9odHk1pGaN-SriWkf4VWdJCqIZKyC7QihPKGKaUu0VXOe1IJxfo36JL1UnZciRV6uvvxlfWCyA4buxQIJ5xgtwRTIONvN7drHOAIIeOjN_h-s2bY7OLs84THpWAXKzXHUrWPvnLYLcmMAfAunKyByVts41xSDNjPuJwOgBl23oxQ7Vu8xsnMLk4-g8MleRPeotdbEzK8e7nX6Nftzc_NffPw_e7LZv3QWE6G0nBBGRk7xx0HJ0BJx2jHxOAUkXxrGCdbxwewwCkZRtc7QzsJTFCnOkGl7a7Rx7PvIcXfC-Si6xMWQjAzxCVrKmSlCaWiovyM2hRzTrDVh-Qnk06aEv28hN7r8xL6eQlNOl17rrIPLwnLOIH7J_pbfQU-n4HaLhw9JJ2th9mC8wls0S76_yf8AY8-nHs |
CitedBy_id | crossref_primary_10_1016_j_ejps_2017_11_022 crossref_primary_10_1007_s11883_016_0570_9 crossref_primary_10_1016_j_biochi_2015_10_024 crossref_primary_10_1016_j_tem_2016_11_007 crossref_primary_10_3390_nu15143120 crossref_primary_10_1111_bph_14157 crossref_primary_10_1016_j_plipres_2020_101084 crossref_primary_10_1124_pr_117_014373 crossref_primary_10_3389_fendo_2021_761834 crossref_primary_10_1038_s41467_024_49536_y crossref_primary_10_3390_nu11092022 crossref_primary_10_1146_annurev_nutr_071816_064916 crossref_primary_10_1016_j_atherosclerosis_2018_03_041 crossref_primary_10_1002_acn3_676 crossref_primary_10_1002_cpdd_704 |
Cites_doi | 10.1016/j.diabres.2008.10.009 10.1111/dom.12132 10.1177/030006058901700411 10.2337/diabetes.51.1.7 10.2337/diabetes.49.5.701 10.2337/diabetes.48.9.1836 10.1007/BF00422371 10.2337/diab.37.8.1020 10.1001/jama.1990.03450060069031 10.2337/diab.42.11.1559 10.1172/JCI10583 10.1111/j.1476-5381.2009.00349.x 10.1001/archinte.162.14.1568 10.1007/BF00280883 10.1016/S0140-6736(63)91500-9 10.1046/j.1365-2362.2000.00597.x 10.1111/j.1464-5491.1993.tb00011.x 10.1126/scitranslmed.3003877 10.1530/acta.0.1270344 10.2337/diabetes.54.11.3148 10.1371/journal.pbio.1001485 |
ContentType | Journal Article |
Copyright | 2015 Elsevier B.V. Copyright © 2015 Elsevier B.V. All rights reserved. |
Copyright_xml | – notice: 2015 Elsevier B.V. – notice: Copyright © 2015 Elsevier B.V. All rights reserved. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1016/j.ejphar.2015.03.005 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1879-0712 |
EndPage | 101 |
ExternalDocumentID | 10_1016_j_ejphar_2015_03_005 25773496 S0014299915001739 |
Genre | Randomized Controlled Trial Journal Article |
GroupedDBID | --- --K --M -~X .~1 0R~ 1B1 1RT 1~. 1~5 4.4 457 4G. 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AACTN AADPK AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AATCM AAXLA AAXUO ABCQJ ABFNM ABFRF ABJNI ABMAC ABYKQ ABZDS ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE AEBSH AEFWE AEKER AENEX AFKWA AFTJW AFXIZ AGUBO AGWIK AGYEJ AIEXJ AIKHN AITUG AJBFU AJOXV ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AXJTR BKOJK BLXMC C45 CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA HMQ IHE J1W K-O KOM L7B M2V M34 M41 MO0 MOBAO N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 RIG ROL RPZ SDF SDG SDP SES SPCBC SSN SSP T5K TEORI ~G- AAXKI AKRWK CGR CUY CVF ECM EIF NPM .55 .GJ 29G 3O- 53G AAQXK AAYXX ABXDB ADMUD AFJKZ AGHFR AHHHB ASPBG AVWKF AZFZN CITATION FEDTE FGOYB G-2 HMT HVGLF HZ~ R2- SEW SNS SPT SSZ WUQ X7M ZGI 7X8 |
ID | FETCH-LOGICAL-c408t-46120b3d4d4ed6e97d213268d9074fa240fd48ece4108bd5da137e261d93617c3 |
IEDL.DBID | .~1 |
ISSN | 0014-2999 |
IngestDate | Sat Aug 17 03:07:56 EDT 2024 Thu Sep 26 19:00:00 EDT 2024 Sat Sep 28 08:06:20 EDT 2024 Fri Feb 23 02:27:58 EST 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Type 2 diabetes GSK 256073 (PubChem CID 46215799) Non Esterified Fatty Acid (NEFA) HbA1c GSK 256073 Hydroxy-carboxylic acid receptor 2 (HCA2) |
Language | English |
License | Copyright © 2015 Elsevier B.V. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c408t-46120b3d4d4ed6e97d213268d9074fa240fd48ece4108bd5da137e261d93617c3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-News-1 ObjectType-Feature-3 content type line 23 |
OpenAccessLink | http://manuscript.elsevier.com/S0014299915001739/pdf/S0014299915001739.pdf |
PMID | 25773496 |
PQID | 1672610116 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_1672610116 crossref_primary_10_1016_j_ejphar_2015_03_005 pubmed_primary_25773496 elsevier_sciencedirect_doi_10_1016_j_ejphar_2015_03_005 |
PublicationCentury | 2000 |
PublicationDate | 2015-05-15 |
PublicationDateYYYYMMDD | 2015-05-15 |
PublicationDate_xml | – month: 05 year: 2015 text: 2015-05-15 day: 15 |
PublicationDecade | 2010 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands |
PublicationTitle | European journal of pharmacology |
PublicationTitleAlternate | Eur J Pharmacol |
PublicationYear | 2015 |
Publisher | Elsevier B.V |
Publisher_xml | – name: Elsevier B.V |
References | Lauring, Taggart, Tata, Dunbar, Caro, Cheng (bib7) 2012; 4 Randle, Garland, Hales, Newholme (bib13) 1963; 1 Shulman (bib19) 2000; 106 Vaag, Beck-Nielsen (bib20) 1992; 127 Worm, Henricksen, Vaag, Thye-Rønn, Melander, Beck-Nieldsen (bib22) 1994; 78 Mohan, Yang, Son, Xu, Noble, Landon (bib11) 2009; 83 Baldeweg, Golay, Natali, Balkau, del Prato, Coppack (bib2) 2000; 30 Lavezzari, Milanesi, Oggioni, Pamparana (bib8) 1989; 17 Paolisso, Tataranni, Foley, Bogardus, Howard, Ravussin (bib12) 1995; 38 Roden, Stingl, Chandramouli, Schumann, Hofer, Landau (bib15) 2000; 49 Garg, Grundy (bib4) 1990; 264 Matthews, Hosker, Rudenski, Naylor, Treacher, Turner (bib9) 1985; 28 Saloranta, Groop, Ekstrand, Franssila-Kallunki, Eriksson, Taskinen (bib16) 1993; 10 Reaven, Hollenbeck, Jeng, Wu, Chen (bib14) 1988; 37 Bajaj, Suraamornkul, Romanelli, Cline, Mandarino, Shulman (bib1) 2005; 54 Grundy, Vega, McGovern, Tulloch, Kendall, Fitz-Patrick (bib6) 2002; 162 Santomauro ATMG, Silva, Rocha, Santos, Ursich (bib18) 1999; 48 Dobbins, Shearn, Byerly, Gao, Mahar, Napolitano (bib3) 2013; 15 McGarry (bib10) 2002; 51 Saloranta, Taskinen, Widen, Harkonen, Melander, Groop (bib17) 1993; 42 Girousse, Tavernier, Valle, Moro, Mejhert, Dinel (bib5) 2013; 11 Vosper (bib21) 2009; 158 Saloranta (10.1016/j.ejphar.2015.03.005_bib16) 1993; 10 Girousse (10.1016/j.ejphar.2015.03.005_bib5) 2013; 11 Vosper (10.1016/j.ejphar.2015.03.005_bib21) 2009; 158 Worm (10.1016/j.ejphar.2015.03.005_bib22) 1994; 78 Dobbins (10.1016/j.ejphar.2015.03.005_bib3) 2013; 15 McGarry (10.1016/j.ejphar.2015.03.005_bib10) 2002; 51 Mohan (10.1016/j.ejphar.2015.03.005_bib11) 2009; 83 Saloranta (10.1016/j.ejphar.2015.03.005_bib17) 1993; 42 Shulman (10.1016/j.ejphar.2015.03.005_bib19) 2000; 106 Garg (10.1016/j.ejphar.2015.03.005_bib4) 1990; 264 Randle (10.1016/j.ejphar.2015.03.005_bib13) 1963; 1 Vaag (10.1016/j.ejphar.2015.03.005_bib20) 1992; 127 Roden (10.1016/j.ejphar.2015.03.005_bib15) 2000; 49 Baldeweg (10.1016/j.ejphar.2015.03.005_bib2) 2000; 30 Lauring (10.1016/j.ejphar.2015.03.005_bib7) 2012; 4 Lavezzari (10.1016/j.ejphar.2015.03.005_bib8) 1989; 17 Reaven (10.1016/j.ejphar.2015.03.005_bib14) 1988; 37 Santomauro ATMG (10.1016/j.ejphar.2015.03.005_bib18) 1999; 48 Bajaj (10.1016/j.ejphar.2015.03.005_bib1) 2005; 54 Paolisso (10.1016/j.ejphar.2015.03.005_bib12) 1995; 38 Grundy (10.1016/j.ejphar.2015.03.005_bib6) 2002; 162 Matthews (10.1016/j.ejphar.2015.03.005_bib9) 1985; 28 |
References_xml | – volume: 264 start-page: 723 year: 1990 end-page: 726 ident: bib4 article-title: Nicotinic acid as therapy for dyslipidemia in noninsulin-dependent diabetes mellitus publication-title: J. Am. Med. Assoc. contributor: fullname: Grundy – volume: 48 start-page: 1836 year: 1999 end-page: 1841 ident: bib18 article-title: Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and non diabetic subjects publication-title: Diabetes contributor: fullname: Ursich – volume: 158 start-page: 429 year: 2009 end-page: 441 ident: bib21 article-title: Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia publication-title: Br. J. Pharmacol. contributor: fullname: Vosper – volume: 4 year: 2012 ident: bib7 article-title: Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression publication-title: Sci. Transl. Med. contributor: fullname: Cheng – volume: 17 start-page: 373380 year: 1989 ident: bib8 article-title: Results of a phase IV study carried out with Acipimox in type II diabetic patients with concomitant hyperlipoproteinaemia publication-title: J. Int. Med. Res. contributor: fullname: Pamparana – volume: 127 start-page: 344 year: 1992 end-page: 350 ident: bib20 article-title: Effects of prolonged Acipimox treatment on glucose and lipid metabolism and on in vivo insulin sensitivity in patients with non-insulin dependent diabetes mellitus publication-title: Acta Endocrinol. contributor: fullname: Beck-Nielsen – volume: 38 start-page: 1213 year: 1995 end-page: 1217 ident: bib12 article-title: A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM publication-title: Diabetologia contributor: fullname: Ravussin – volume: 54 start-page: 3148 year: 2005 end-page: 3153 ident: bib1 article-title: Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients publication-title: Diabetes contributor: fullname: Shulman – volume: 30 start-page: 45 year: 2000 end-page: 52 ident: bib2 article-title: Insulin resistance, lipid and fatty acid concentrations in 867 healthy Europeans publication-title: Eur. J. Clin. Investig. contributor: fullname: Coppack – volume: 11 start-page: e1001485 year: 2013 ident: bib5 article-title: Partial inhibition of adipose tissue lipolysis improves glucose metabolism and insulin sensitivity without alteration of fat mass publication-title: PLoS Biol. contributor: fullname: Dinel – volume: 10 start-page: 950 year: 1993 end-page: 957 ident: bib16 article-title: Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes publication-title: Diab. Med. contributor: fullname: Taskinen – volume: 106 start-page: 171 year: 2000 end-page: 176 ident: bib19 article-title: Cellular mechanism of insulin resistance publication-title: J. Clin. Investig. contributor: fullname: Shulman – volume: 28 start-page: 412 year: 1985 end-page: 419 ident: bib9 article-title: Homoeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man publication-title: Diabetologia contributor: fullname: Turner – volume: 1 start-page: 785 year: 1963 end-page: 789 ident: bib13 article-title: The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus publication-title: Lancet contributor: fullname: Newholme – volume: 83 start-page: 106 year: 2009 end-page: 116 ident: bib11 article-title: Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea publication-title: Diab. Res. Clin. Pract. contributor: fullname: Landon – volume: 37 start-page: 1020 year: 1988 end-page: 1024 ident: bib14 article-title: Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 publication-title: Diabetes contributor: fullname: Chen – volume: 49 start-page: 701 year: 2000 end-page: 707 ident: bib15 article-title: Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans publication-title: Diabetes contributor: fullname: Landau – volume: 42 start-page: 1559 year: 1993 end-page: 1566 ident: bib17 article-title: Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM publication-title: Diabetes contributor: fullname: Groop – volume: 162 start-page: 1568 year: 2002 end-page: 1576 ident: bib6 article-title: Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial publication-title: Arch. Intern. Med. contributor: fullname: Fitz-Patrick – volume: 78 start-page: 717 year: 1994 end-page: 721 ident: bib22 article-title: Pronounced blood glucose-lowering effect of the antilipolytic drug Acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period publication-title: J. Clin. Endocrinol. Metab. contributor: fullname: Beck-Nieldsen – volume: 15 start-page: 1013 year: 2013 end-page: 1021 ident: bib3 article-title: GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus publication-title: Diab. Obes. Metab. contributor: fullname: Napolitano – volume: 51 start-page: 7 year: 2002 end-page: 18 ident: bib10 article-title: Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes publication-title: Diabetes contributor: fullname: McGarry – volume: 83 start-page: 106 year: 2009 ident: 10.1016/j.ejphar.2015.03.005_bib11 article-title: Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea publication-title: Diab. Res. Clin. Pract. doi: 10.1016/j.diabres.2008.10.009 contributor: fullname: Mohan – volume: 15 start-page: 1013 year: 2013 ident: 10.1016/j.ejphar.2015.03.005_bib3 article-title: GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus publication-title: Diab. Obes. Metab. doi: 10.1111/dom.12132 contributor: fullname: Dobbins – volume: 17 start-page: 373380 year: 1989 ident: 10.1016/j.ejphar.2015.03.005_bib8 article-title: Results of a phase IV study carried out with Acipimox in type II diabetic patients with concomitant hyperlipoproteinaemia publication-title: J. Int. Med. Res. doi: 10.1177/030006058901700411 contributor: fullname: Lavezzari – volume: 51 start-page: 7 year: 2002 ident: 10.1016/j.ejphar.2015.03.005_bib10 article-title: Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes publication-title: Diabetes doi: 10.2337/diabetes.51.1.7 contributor: fullname: McGarry – volume: 49 start-page: 701 year: 2000 ident: 10.1016/j.ejphar.2015.03.005_bib15 article-title: Effects of free fatty acid elevation on postabsorptive endogenous glucose production and gluconeogenesis in humans publication-title: Diabetes doi: 10.2337/diabetes.49.5.701 contributor: fullname: Roden – volume: 48 start-page: 1836 year: 1999 ident: 10.1016/j.ejphar.2015.03.005_bib18 article-title: Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and non diabetic subjects publication-title: Diabetes doi: 10.2337/diabetes.48.9.1836 contributor: fullname: Santomauro ATMG – volume: 38 start-page: 1213 year: 1995 ident: 10.1016/j.ejphar.2015.03.005_bib12 article-title: A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM publication-title: Diabetologia doi: 10.1007/BF00422371 contributor: fullname: Paolisso – volume: 37 start-page: 1020 year: 1988 ident: 10.1016/j.ejphar.2015.03.005_bib14 article-title: Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24h in patients with NIDDM publication-title: Diabetes doi: 10.2337/diab.37.8.1020 contributor: fullname: Reaven – volume: 264 start-page: 723 year: 1990 ident: 10.1016/j.ejphar.2015.03.005_bib4 article-title: Nicotinic acid as therapy for dyslipidemia in noninsulin-dependent diabetes mellitus publication-title: J. Am. Med. Assoc. doi: 10.1001/jama.1990.03450060069031 contributor: fullname: Garg – volume: 42 start-page: 1559 year: 1993 ident: 10.1016/j.ejphar.2015.03.005_bib17 article-title: Metabolic consequences of sustained suppression of free fatty acids by acipimox in patients with NIDDM publication-title: Diabetes doi: 10.2337/diab.42.11.1559 contributor: fullname: Saloranta – volume: 106 start-page: 171 year: 2000 ident: 10.1016/j.ejphar.2015.03.005_bib19 article-title: Cellular mechanism of insulin resistance publication-title: J. Clin. Investig. doi: 10.1172/JCI10583 contributor: fullname: Shulman – volume: 158 start-page: 429 year: 2009 ident: 10.1016/j.ejphar.2015.03.005_bib21 article-title: Niacin: a re-emerging pharmaceutical for the treatment of dyslipidaemia publication-title: Br. J. Pharmacol. doi: 10.1111/j.1476-5381.2009.00349.x contributor: fullname: Vosper – volume: 162 start-page: 1568 year: 2002 ident: 10.1016/j.ejphar.2015.03.005_bib6 article-title: Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial publication-title: Arch. Intern. Med. doi: 10.1001/archinte.162.14.1568 contributor: fullname: Grundy – volume: 28 start-page: 412 year: 1985 ident: 10.1016/j.ejphar.2015.03.005_bib9 article-title: Homoeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man publication-title: Diabetologia doi: 10.1007/BF00280883 contributor: fullname: Matthews – volume: 1 start-page: 785 year: 1963 ident: 10.1016/j.ejphar.2015.03.005_bib13 article-title: The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus publication-title: Lancet doi: 10.1016/S0140-6736(63)91500-9 contributor: fullname: Randle – volume: 30 start-page: 45 year: 2000 ident: 10.1016/j.ejphar.2015.03.005_bib2 article-title: Insulin resistance, lipid and fatty acid concentrations in 867 healthy Europeans publication-title: Eur. J. Clin. Investig. doi: 10.1046/j.1365-2362.2000.00597.x contributor: fullname: Baldeweg – volume: 10 start-page: 950 year: 1993 ident: 10.1016/j.ejphar.2015.03.005_bib16 article-title: Different acute and chronic effects of acipimox treatment on glucose and lipid metabolism in patients with type 2 diabetes publication-title: Diab. Med. doi: 10.1111/j.1464-5491.1993.tb00011.x contributor: fullname: Saloranta – volume: 78 start-page: 717 year: 1994 ident: 10.1016/j.ejphar.2015.03.005_bib22 article-title: Pronounced blood glucose-lowering effect of the antilipolytic drug Acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period publication-title: J. Clin. Endocrinol. Metab. contributor: fullname: Worm – volume: 4 year: 2012 ident: 10.1016/j.ejphar.2015.03.005_bib7 article-title: Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression publication-title: Sci. Transl. Med. doi: 10.1126/scitranslmed.3003877 contributor: fullname: Lauring – volume: 127 start-page: 344 year: 1992 ident: 10.1016/j.ejphar.2015.03.005_bib20 article-title: Effects of prolonged Acipimox treatment on glucose and lipid metabolism and on in vivo insulin sensitivity in patients with non-insulin dependent diabetes mellitus publication-title: Acta Endocrinol. doi: 10.1530/acta.0.1270344 contributor: fullname: Vaag – volume: 54 start-page: 3148 year: 2005 ident: 10.1016/j.ejphar.2015.03.005_bib1 article-title: Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients publication-title: Diabetes doi: 10.2337/diabetes.54.11.3148 contributor: fullname: Bajaj – volume: 11 start-page: e1001485 year: 2013 ident: 10.1016/j.ejphar.2015.03.005_bib5 article-title: Partial inhibition of adipose tissue lipolysis improves glucose metabolism and insulin sensitivity without alteration of fat mass publication-title: PLoS Biol. doi: 10.1371/journal.pbio.1001485 contributor: fullname: Girousse |
SSID | ssj0005925 |
Score | 2.2829382 |
Snippet | This study investigated safety and efficacy of GSK256073, an in vitro potent, selective GPR109A agonist, for treatment of subjects with type 2 diabetes... |
SourceID | proquest crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 95 |
SubjectTerms | Aged Blood Glucose - analysis Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Double-Blind Method Fatty Acids, Nonesterified - blood Female Fructosamine - blood Glycated Hemoglobin A - analysis GSK 256073 HbA1c Humans Hydroxy-carboxylic acid receptor 2 (HCA2) Insulin - blood Male Middle Aged Non Esterified Fatty Acid (NEFA) Receptors, G-Protein-Coupled - agonists Receptors, Nicotinic Treatment Outcome Type 2 diabetes Xanthines - administration & dosage Xanthines - pharmacokinetics Xanthines - pharmacology Xanthines - therapeutic use |
Title | GSK256073 acutely regulates NEFA levels via HCA2 agonism but does not achieve durable glycaemic control in type 2 diabetes. A randomised trial |
URI | https://dx.doi.org/10.1016/j.ejphar.2015.03.005 https://www.ncbi.nlm.nih.gov/pubmed/25773496 https://search.proquest.com/docview/1672610116 |
Volume | 755 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBYhvfRS-u72EaZQcooT25IfezRLttuGLoEmkJuQPHK6YWMva7uwl_6E_ubO-NG0h1Do0Ua2hWY88430zYwQH6xV1sdYeijRespRgGJk7nuBLaSLUxdZ5EThL8t4cak-X0VXe2I25sIwrXKw_b1N76z1cOdkWM2TzWrFOb4BG9MpQRpSK8lJfIqcEen08Y8_aB7TcOhioDwePabPdRwvd7P5ZrgqaBD1pU6j-9zTffCzc0Pzx-LRgB8h66f4ROy58qk4PO8LUO-O4OIun6o-gkM4vytNvXsmfn78esboI5Fg8rZx6x1s-2b0robl6TyDNZOIavi-MrCYZSGYa_rp61uwbQNY0aiyaoAJmDQOsN1y5hVcr3e5YZY9DMx3WJXAm7sQwri5ewwZkF_EihTLIXTdQp6Ly_npxWzhDR0ZvFz5aeMpwkO-lahQOYzdNMGQotk4RQ6xC0PooECVutypwE8tRmgCmTgK0nAqCSrl8oXYL6vSvRKgEufLIk-LlF4X5ZZ0aRonyhaxRJMW4UR4oyD0pi-8oUdG2o3uBadZcNqXmgQ3EckoLf2XAmnyDf948v0oXE1LwAcmpnRVW-sgTmjufFQ1ES97qf-eC5m6hIvtv_7v774RD_mKqQhB9FbsN9vWvSOE09iDToUPxIPs09li-QuaS_sx |
link.rule.ids | 315,786,790,4521,24144,27957,27958,45620,45714 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwELYoHNpLRd8LfUylihOBJHZex9WK7VJghcQicbPs2KGLtslqkyDthZ_Ab-5MHoUeUKVeEyexPJOZb-xvZhj7prXQrgm5Y7jRjrAYoCieuo6nM27D2AbaUKLw2TScXIofV8HVBhv1uTBEq-xsf2vTG2vdXTnsVvNwOZ9Tjq9HxjRBSINqxZNnbIvgPPVvOLh7xPNI_K6NgXBoeJ8_15C87M3yp6KyoF7Q1joNnvJPT-HPxg-Nt9nLDkDCsJ3jK7Zh89ds77ytQL3eh9lDQlW5D3tw_lCbev2G3X-_OCH4EXFQaV3ZxRpWbTd6W8L0aDyEBbGISridK5iMhj6oa_zry1-g6wpMgaPyogJiYOI4MPWKUq_gerFOFdHsoaO-wzwH2t0FH_rd3QMYAjpGU6BmWQNNu5C37HJ8NBtNnK4lg5MKN64cgYDI1dwII6wJbRIZH8PZMDYUY2cK4UFmRGxTKzw31iYwyuORxSjNJByxUsrfsc28yO0HBiKyLs_SOIvxdUGqUZmSMBI6C7lRceYPmNMLQi7byhuyp6TdyFZwkgQnXS5RcAMW9dKSf2mQROfwjye_9sKVuAR0YqJyW9Sl9MII505nVQP2vpX6n7mgrYuo2v7Of3_3C3s-mZ2dytPj6ckue0F3iJfgBR_ZZrWq7SeEO5X-3Kjzb1qS_MM |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=GSK256073+acutely+regulates+NEFA+levels+via+HCA2+agonism+but+does+not+achieve+durable+glycaemic+control+in+type+2+diabetes.+A+randomised+trial&rft.jtitle=European+journal+of+pharmacology&rft.au=Dobbins%2C+Robert&rft.au=Byerly%2C+Robert&rft.au=Gaddy%2C+Riley&rft.au=Gao%2C+Feng&rft.date=2015-05-15&rft.pub=Elsevier+B.V&rft.issn=0014-2999&rft.eissn=1879-0712&rft.volume=755&rft.spage=95&rft.epage=101&rft_id=info:doi/10.1016%2Fj.ejphar.2015.03.005&rft.externalDocID=S0014299915001739 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0014-2999&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0014-2999&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0014-2999&client=summon |